Arni Entresto denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for arni entresto are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Entresto as "Experimental or Investigational"

Entresto (sacubitril/valsartan) received FDA approval for its primary heart failure indication in 2015, and the FDA has since approved an additional indication. An "experimental or investigational" denial for an FDA-approved therapy in an on-label indication is a strong candidate for appeal, because the regulatory and clinical evidence basis for Entresto is well established and reflected in major cardiology guidelines.

This type of denial most commonly occurs in one of two scenarios: (1) the claim is for an off-label use that BCBS has not yet recognized in its medical policy, or (2) BCBS's medical policy has not been updated to reflect the current FDA-approved label or guideline landscape. Identifying which scenario applies will sharpen the appeal.

## Why This Is Appealable

If the use is on-label, FDA approval itself is the primary rebuttal. BCBS cannot credibly characterize an FDA-approved, on-label use as experimental. The appeal should cite the FDA approval, the current indication statement from the prescribing information, and the relevant ACC/AHA guideline organization's position on ARNI therapy — without quoting specific statistics, but citing the guideline's existence and the professional society that publishes it. If the use is off-label, the appeal should demonstrate peer-reviewed, published support for the use and explain why it is not experimental in the clinical sense.

## Federal Appeal Framework

• Internal appeal: File within the deadline on the denial letter. Include the FDA approval documentation and a prescriber medical-necessity letter.
• ACA §2719 external review: Available after exhausting internal appeals. IRO reviewers are clinicians who evaluate whether the denial was consistent with accepted medical practice. This is a particularly strong venue for experimental denials of FDA-approved therapies. Window is approximately four months from final internal denial.
• Expedited external review: Available for urgent cardiac situations where delay could cause serious harm.
• ERISA §503: Requires BCBS to disclose which medical policy provision supports the "experimental" classification and to conduct a full-and-fair review.

## What to Gather

• FDA approval documentation: Print the current prescribing information from the FDA label database (DailyMed) showing the approved indication(s).
• Diagnosis and functional-status documentation: Echo report, clinical notes, and any relevant lab values confirming the patient's diagnosis falls within the FDA-labeled indication — without asserting specific numeric cutoffs.
• Prescriber medical-necessity letter: The treating cardiologist should state that Entresto is being prescribed within its FDA-approved indication and is consistent with current ACC/AHA heart failure guidelines.
• Guideline reference: Reference the ACC/AHA Heart Failure Guideline by organization and publication year (confirm the current version); do not quote specific recommendation grades or statistics.

## Criteria-Mapping Structure

In the appeal letter, list BCBS's stated basis for the "experimental" classification from the denial letter. For each stated basis, provide the corresponding FDA label language or peer-reviewed reference that refutes it. This structured point-by-point rebuttal is the most persuasive format for this denial type.